What Adaptive Biotechnologies Corporation's executives and directors are doing with their own shares, from SEC Form 3/4/5 filings — separating what the filings state (awards, withholding, disclosed plans) from what only the pattern of dates shows.
| 3 months | 12 months | |
|---|---|---|
| Open-market buys | 0 | 0 |
| Sells | 49 | 162 |
| Total trades | 79 | 306 |
| 3 months | 12 months | |
|---|---|---|
| Acquired | 976,210 | 5,244,871 |
| Disposed | 1,145,502 | 7,079,044 |
| Net activity | −169,292 | −1,834,173 |
View rich charts and dive into the patterns of specific insiders — who is accumulating, who is winding down, and which sale explanations the filings actually support.
| Insider | Relation | Date | Transaction | Shares | Price | Value | Shares held |
|---|---|---|---|---|---|---|---|
| Rubinstein Julie | President and COO | Oct 26 | Disclosed 10b5-1 sale · S | −3,378 | $26.30 | −$88.8K | 377,802 |
| Rubinstein Julie | President and COO | Oct 26 | Disclosed 10b5-1 sale · S | −8,503 | $25.94 | −$221K | 381,180 |
| Rubinstein Julie | President and COO | Oct 26 | Exercise / conversion · M | +11,881 | $12.14 | +$144K | 389,683 |
| Rubinstein Julie | President and COO | Oct 23 | Disclosed 10b5-1 sale · S | −7,381 | $25.28 | −$187K | 377,802 |
| Rubinstein Julie | President and COO | Oct 23 | Disclosed 10b5-1 sale · S | −4,500 | $24.50 | −$110K | 385,183 |
| Rubinstein Julie | President and COO | Oct 23 | Exercise / conversion · M | +11,881 | $12.14 | +$144K | 389,683 |
| Rubinstein Julie | President and COO | Oct 22 | Disclosed 10b5-1 sale · S | −1,700 | $25.29 | −$43K | 377,802 |
| Rubinstein Julie | President and COO | Oct 22 | Disclosed 10b5-1 sale · S | −10,181 | $24.38 | −$248K | 379,502 |
| Rubinstein Julie | President and COO | Oct 22 | Exercise / conversion · M | +11,881 | $12.14 | +$144K | 389,683 |
| Rubinstein Julie | President and COO | Oct 21 | Disclosed 10b5-1 sale · S | −5,882 | $25.57 | −$150K | 377,802 |
| Rubinstein Julie | President and COO | Oct 21 | Disclosed 10b5-1 sale · S | −5,999 | $25.25 | −$151K | 383,684 |
| Rubinstein Julie | President and COO | Oct 21 | Exercise / conversion · M | +11,881 | $12.14 | +$144K | 389,683 |
| Rubinstein Julie | President and COO | Oct 20 | Disclosed 10b5-1 sale · S | −100 | $24.85 | −$2.49K | 377,802 |
| Rubinstein Julie | President and COO | Oct 20 | Disclosed 10b5-1 sale · S | −11,781 | $24.53 | −$289K | 377,902 |
| Rubinstein Julie | President and COO | Oct 20 | Exercise / conversion · M | +11,881 | $12.14 | +$144K | 389,683 |
| Rubinstein Julie | President and COO | Oct 19 | Disclosed 10b5-1 sale · S | −11,881 | $24.05 | −$286K | 377,802 |
| Rubinstein Julie | President and COO | Oct 19 | Exercise / conversion · M | +11,881 | $12.14 | +$144K | 389,683 |
| Rubinstein Julie | President and COO | Oct 16 | Disclosed 10b5-1 sale · S | −300 | $25.45 | −$7.64K | 377,802 |
| Rubinstein Julie | President and COO | Oct 16 | Disclosed 10b5-1 sale · S | −11,581 | $24.21 | −$280K | 378,102 |
| Rubinstein Julie | President and COO | Oct 16 | Exercise / conversion · M | +11,881 | $12.14 | +$144K | 389,683 |
Loading...